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Abstract
Background: Traumatic brain injury (TBI) is a critical public health and socio-economic problem worldwide. A
growing body of evidence supports the involvement of inflammatory events in TBI. It has been reported that
resident microglia and infiltrating monocytes promote an inflammatory reaction that leads to neuronal death and
eventually behavioral and cognitive impairment. Currently, there is no effective treatment for TBI and the
development of new therapeutic strategies is a scientific goal of highest priority. Laquinimod, an orally
administered neuroimmunomodulator initially developed for the treatment of multiple sclerosis, might be a
promising neuroprotective therapy for TBI. Herein, we aim to investigate the hypothesis that laquinimod will
reduce the central nervous system (CNS) damage caused by TBI.
Methods: To test our hypothesis, Ccr2rfp/+ Cx3cr1gfp/+ mice were submitted to a moderate TBI induced by
fluid percussion. Sham controls were submitted only to craniotomy. Mice were treated daily by oral gavage
with laquinimod (25 mg/kg) 7 days before and 3 days after TBI. The brains of mice treated or not treated
with laquinimod were collected at 3 and 120 days post injury, and brain morphological changes, axonal
injury, and neurogenesis were evaluated by microscopy analysis. We also isolated microglia from infiltrating
monocytes, and the expression of immune gene mRNAs were analyzed by employing a quantitative
NanoString nCounter technique.
Results: Laquinimod prevented ventricle enlargement caused by TBI in the long term. Immunohistochemical analyses
revealed decreased axonal damage and restored neurogenesis in the laquinimod-treated TBI group at early stage
(3 days post injury). Notably, laquinimod inhibited the monocytes infiltration to the brain. Hierarchial clustering
demonstrated that the microglial gene expression from the TBI group treated with laquinimod resembles the sham
group more than the TBI-water control group.
Conclusions: Administration of laquinimod reduced lesion volume and axonal damage and restored neurogenesis
after TBI. Laquinimod might be a potential therapy strategy to improve TBI long-term prognosis.
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Background
Traumatic brain injury (TBI) is a critical public health
and socio-economic problem worldwide. It is the leading
cause of death and disability among children and young
adults, although the incidence in the elderly population
has also been rising [1]. Data from the Centers for Dis-
ease Control and Prevention (CDC) indicate that each
year in the USA, 1.7 million people sustain a TBI, with
1.4 million of these injured individuals treated in emer-
gency departments, with around 275,000 hospitalizations
and 52,000 fatalities [2]. It is worth mentioning that
neurological, behavioral, and cognitive deficits are well-
known sequelae of TBI, which lead to long-term func-
tional impairment and decrease in quality of life [3].
Multiple inflammatory responses follow TBI. Damage-
associated molecular patterns (DAMPs) activate micro-
glia and resident mononuclear phagocytes in the central
nervous system (CNS), and microglial activation leads to
further neuronal damage through secretion of inflamma-
tory cytokines and reactive specimens among other
mechanisms [4, 5]. These responses may determine
whether microglial cell activity leads to the clearance of
tissue debris and subsequent resolution of the inflamma-
tory response or leads to chronic inflammation. In
addition to microglial activation, peripherally derived
macrophages and perivascular macrophages also partici-
pate in the inflammatory response. As a result of passage
time or environmental factors, microglia and/or periph-
erally derived monocytes and macrophages may acquire
an anti-inflammatory phenotype, which is associated
with the increased secretion of neurotrophic factors and
enhanced phagocytic activity, which cause them to re-
move debris and promote regeneration [5]. At present,
however, how microglia and/or monocytes become
chronically activated with exaggerated and consequently
neurotoxic inflammatory response is poorly understood.
Therefore, it is important to reveal the molecular mech-
anisms regulating deleterious microglial activation and
to regulate the microglial and/or monocyte response to
halt progressive neuronal damage.
Laquinimod is an immunomodulatory oral drug devel-
oped for the treatment of multiple sclerosis (MS) [6–8]
and has been studied in clinical trials for other diseases
including Huntington’s disease [9], Crohn’s disease [10],
and lupus nephritis [11]. Laquinimod inhibited the infil-
tration of inflammatory monocytes into the CNS in ex-
perimental autoimmune encephalomyelitis (EAE), an
animal model of MS [12]. In addition, CCR2 and CCL2
levels, a chemokine signaling known to be crucial for
monocyte chemotaxis, were not elevated in the spinal
cord of laquinimod-treated EAE mice [12]. In cultured
human monocytes, laquinimod inhibited the phosphor-
ylation state of the inflammatory signaling pathways
p38/MAPK and JNK. On the other hand, the activation
of human microglia by lipopolysaccharide (LPS) in-
creased the levels of several pro- and anti-inflammatory
cytokines, including tumor necrosis factor (TNF) and
interleukin (IL)-6 and IL-10, which were attenuated by
laquinimod [13]. Laquinimod also inhibited LPS-
elevated phosphorylation of JNK, AKT, and 90RSK, but
not of ERK1/2 and p38MAPK in human microglia [13].
Taken together, these in vivo and in vitro studies pro-
vided evidence that laquinimod modulates inflammation
and may exert its effects by specifically influencing
microglia and infiltrating monocyte functions.
In this scenario, we aim to investigate the effects of
laquinimod treatment for lateral fluid percussion TBI in
adult mice, by modifying microglia and infiltrating
monocytes functions.
Methods
Mice
Ccr2rfp/+ Cx3cr1gfp/+ mice in which monocyte-derived
macrophages and microglia are labeled with red fluores-
cent protein (RFP) and green fluorescent protein (GFP),
respectively [14] were generated by crossbreeding
Ccr2rfp/rfp::C57BL/6 mice (Jackson laboratory) [14] with
Cx3cr1gfp/gfp::C57BL/6 mice (Jackson laboratory) [15].
Animals were housed at the Cleveland Clinic Biological
Resources Unit, a facility fully accredited by the Associ-
ation of Assessment and Accreditation of Laboratory
Animal Care. All procedures were approved by the Insti-
tutional Animal Care and Use Committee of the
Cleveland Clinic.
Laquinimod administration
Laquinimod (LAQ; originally ABR-215062) was synthe-
sized at TEVA Pharmaceutical Industries, Ltd. The com-
pound was dissolved in purified water (25 mg/kg) and
administered orally every day by oral gavage in a volume
of 100 μL. LAQ was given for 7 days before the TBI for
preventive treatment and for 3 days after the TBI for
therapeutic treatment. The solution was stored at 4 °C
and used within 1 week of preparation. Control mice re-
ceived a volume of 100 μL of water by oral gavage. Each
group contained between 10 and 15 animals.
Traumatic brain injury
Lateral fluid percussion injury (LFPI) was induced in 8-
week-old mice as described before [16]. Briefly, mice
were anesthetized with ketamine (35.7 mg/mL)/xylazine
(2.6 mg/mL), and positioning on a stereotactic frame, a
craniotomy (3 mm in diameter) was made between the
midline, bregma, and lambda. A plastic hub was at-
tached around the craniotomy. After 24 h of the craniot-
omy, mice were anesthetized with ketamine and
xylazine, and the LFPI was produced at 1.0 atm, result-
ing in a moderate, focal injury with a distinct cortical
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cavity. The skin incision was sutured. Sham controls re-
ceived craniotomy, and the same amount of anesthetics
without the trauma procedure.
Histology
Mice were euthanized 3 days or 120 days after the TBI.
All mice were deeply anesthetized with ketamine and
xylazine and perfused transcardially with PBS, followed
by PBS containing 4% paraformaldehyde. After perfu-
sion, the brains were post-fixed in a solution of 4% para-
formaldehyde at 4 °C for 24 h. Free-floating sections of
the brain were prepared as previously described [17].
For immunofluorescence assay, sections were blocked
with 10% normal serum for 1 h and stained with primary
antibodies at 4 °C overnight. After washing with PBST
(PBS with 0.1% Triton X-100) three times, the sections
were incubated with secondary antibodies at room
temperature for 2 h and mounted in ProLong Gold anti-
fade reagent with DAPI (Life technologies) or in hardset
FluorSave Reagent (Calbiochem). Antibodies used in-
clude mouse anti-GFP (UCDavis/NIH NeuroMab Facil-
ity, 1:8000), rabbit anti-RFP (Abcam, 1:1000), Alexa
Fluor 488 goat anti-mouse IgG (Invitrogen, 1:1000), and
Alexa Fluor 594 goat anti-rabbit IgG (Invitrogen,
1:1000).
Axonal pathology was assessed with amyloid precursor
protein (APP) staining, and neurogenesis was assessed
with doublecortin (DCX) staining. The sections were in-
cubated in 0.3% H2O2 for 30 min at room temperature
(RT) to inactivate endogenous peroxidases. Antigen re-
trieval was performed in × 1 target retrieval solution
(Dako Cytomation) containing 0.5% Tween in PBS at
85 °C for 10 min. After blocking in 10% normal goat
serum (NGS), primary rabbit anti-APP antibody (Invitro-
gen, 1:1000) or rabbit anti-DCX antibody (Cell signaling,
1:250) was applied overnight at 4 °C and secondary bio-
tinylated goat anti-rabbit antibody (Vector, 1:200 for
APP, 1:1000 for DCX) was applied for 1 h at RT. The
signal was detected using the ABC Elite Kit (Vector) and
DAB substrate kit (Vector) according to the manufac-
turer’s instructions. Sections were allowed to dry and
were coverslipped with hardset mounting medium
(Fisher Scientific). Three sections were stained for each
animal and averaged after quantification.
For cresyl violet staining, brain sections were washed
three times in 0.1% PBST for 10 min then mounted on
glass slides. The slides were dried and immersed in xy-
lene and graded ethanol, and de-ionized water for 3 min
each. The slides were stained for 8 min in filtered cresyl
violet solution, and then briefly rinsed in de-ionized
water. The slides were dehydrated again in graded etha-
nol for 2 min each. The slices were placed in xylene for
another 5 min and coverslipped.
Measurement of brain atrophy
Brain sections were subjected to cresyl violet staining for
histologic assessment of damage and the adjacent sec-
tions were processed for immunohistochemistry. The
brain slices were photographed by Leica SCN400F
microscope, and lesion volumes were measured by an
investigator masked to the study groups with ImageJ
software (National Institutes of Health).
Imaging
Sections stained with GFP and RFP as previously de-
scribed [18]. Briefly, slides were imaged on a Leica
CTR5500 microscope equipped with a QImaging Retiga
EXi FAST 13941 MONO camera at × 10 magnification.
Tiling of consecutive fields of view was employed to
capture the whole section and all sections from a mouse
using ImagePro Plus software to drive the microscope.
Both GFP (microglia) and RFP (monocyte) channels
were recorded.
Cell isolation and flow cytometry
Mice were deeply anesthetized with ketamine and xyla-
zine and perfused with phosphate-buffered saline (PBS)
transcardially at 3 days after the TBI. After the brains
were minced and dissociated by an enzyme (Myltenyl
Biotec), single mononuclear cells were isolated using a
Percoll density gradient. Cells were subsequently stained
with anti-CD45-Qdot605NC (eBioscience) and anti-
Ly6C-Pecy7 (Biolegend). Microglia were CD45low
CX3CR1high CCR2neg and monocytes were CD45high
CX3CR1low-neg CCR2+. Infiltrated monocytes were de-
fined as CD45high CX3CR1low-neg CCR2+ Ly6Chigh cells.
Stained cells were analyzed on a LSR-II (BD Biosciences,
San Jose, CA) or sorted on a FACSAria II (BD Biosci-
ences, San Jose, CA) running Diva6. Data were analyzed
with FlowJo 9 software (Treestar, Ashland, OR).
MG468 chip design
The MG468 chip was designed using the quantitative
NanoString nCounter platform [19]. Selection of genes
is based on analyses that identified genes and proteins
which are specifically or highly expressed in adult mouse
microglia plus 40 inflammation-related genes which
were significantly affected in EAE, APP-PS1, and SOD1
mice (MG400, [19]). MG468 contains additional 48 in-
flammation- and phagocytosis-related genes [20].
Gene expression
Mononuclear cells were prepared from brains as previ-
ously described [21, 22]. Cells were sorted on a BD FAC-
SAria II by gating on CD45low GFPhigh for microglia and
CD45high RFP+ for monocytes. RNA was isolated from
FACS-sorted cells mixed from 5 to 13 mice from six
separate experiments per group in TRIzol Reagent
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(Ambion) according to the manufacturer’s protocol.
RNA samples were analyzed by nCounter gene expres-
sion analysis and quantified with the nCounter Digital
Analyzer (NanoString Technologies). Expressions of 468
genes were analyzed using nCounter GX Mouse Inflam-
mation kit. To minimize technical (non-biological) vari-
ability among arrays, densitometry values between arrays
were normalized using the Robust Multichip Average
function and further transformed to the logarithmic
scale (log2). Gene expression levels in each sample were
normalized against the geometric mean of six house-
keeping genes including Cltc, Gapdh, Gusb, Hprt1, Pgk1,
and Tubb5. A cutoff was introduced at the value of the
highest negative control present on the chip. Fold
changes were calculated using the average of each group.
For each experiment, the fold changes were calculated
comparing the experimental group to their appropriate
controls. Based on the normalized gene expression levels
of NanoString-based chips, a two tailed Student’s t test
assuming equal variance was applied to each gene to
compare the difference between the TBI group and the
control group. Fold change cutoffs of > 1.5 were used to
evaluate gene expression changes with number.
Hierarchical cluster analysis
Hierarchical cluster analysis was performed using Mul-
tiple Experiment Viewer (MeV) software to see how data
aggregate, and a heat map was generated with pluripo-
tency genes.
Real-time PCR
Total RNA was extracted using RNA clean and con-
centration kit (Epigenetics) according to the manufac-
turer’s protocol. Total RNA (50 ng/μl) was used in
reverse transcription reaction (Applied Biosystems)
and 3 ng RNA in 5 μL reverse transcription reaction
with specific RNA probes (Applied Biosystems). qPCR
reactions were performed in duplicates. Primers and
probes for IL − 6 (Taqman Gene Expression Assay ID
Mm00446190) and iNOS (Mm00440502) were pur-
chased from Applied Biosystems. mRNA levels were
normalized relative to GAPDH (Applied Biosystems,
4351309), by the formula 2^(−ΔCt), where ΔCt =
CtmiR-X-CtGAPDH. All data are means of duplicates
and the standard errors of mean were calculated be-
tween duplicates. Real-time PCR reactions were per-
formed using Vii7 (Applied Biosystems). All qRT-
PCRs were performed in duplicate, and data are pre-
sented as means ± standard errors of mean (s.e.m).
Statistical analysis
Unless otherwise indicated, data are presented as
mean ± SEM from at least three independent experi-
ments, and P < 0.05 was considered statistically signifi-
cant. Statistical analysis of the data was concluded
using a non-parametric test (Man-Whitney or
Kruskal-Wallis tests) followed by a Dunn’s multiple
comparison test. All data were analyzed using Graph-
Pad PRISM 5 software (Sandiego, CA).
Results
Laquinimod treatment attenuated the lateral ventricle
volume following TBI
TBI is known to cause permanent structural and
functional changes in the brain and increase the risk
for neuronal loss and brain atrophy which conse-
quently result in dementia [23, 24]. We first evaluated
the effect of laquinimod in the long-term outcome of
TBI. Images obtained from lateral ventricles slices
stained with cresyl violet of TBI mice 120 days fol-
lowing the traumatic event revealed a significant en-
largement of the lateral ventricles compared to sham
animals (*p < 0.05) (Fig. 1a). Although there was no
statistical difference in hippocampal volume (data not
shown), hippocampal deformation on the ipsilateral
side of the TBI-water group was not observed in the
TBI-laquinimod group. Importantly, laquinimod
treatment significantly prevented long-term increase
in lateral ventricles volume caused by TBI (*p < 0.05)
(Fig. 1b).
a b
Fig. 1 Laquinimod prevents traumatic brain injury (TBI)-induced long-term lateral ventricle enlargement. a Representative × 10 images of brain
sections, stained with cresyl violet, from sham and TBI mice (120 days following the brain injury) treated with laquinimod (LAQ) or vehicle (water).
b A significant increase in lateral ventricle volume was found in TBI-water group, which was significantly prevented by laquinimod treatment.
Symbols denote significant differences between groups. Error bars indicate mean ± s.e.m. (n = 3–4/group). *p < 0.05
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Laquinimod reduced axonal damage and restored
hippocampal neurogenesis followed by TBI
Next, we addressed the neuropathological features at
acute phase (3 days post injury). Diffuse axonal injury is
one of the most common types of brain injury following
TBI and independently contributes to significant mor-
bidity and mortality. Using immunohistochemistry tech-
nique, we evaluated axonal damage in the lesion
ipsilateral corpus callosum and hippocampus. Consistent
with previous studies [18, 25], there was an increase in
APP-positive profiles in the body of the corpus callosum
as well as in hippocampus in the TBI-water group
(Fig. 2a). Laquinimod treatment significantly prevented
axonal damage in both areas (Fig. 2a–c). Furthermore, in
the immunohistochemistry for the neuronal migration
protein, doublecortin (DCX) revealed reduced hippo-
campal neurogenesis in dentate gyrus in the TBI-water
group, which was restored to the levels observed in
sham controls in TBI-laquinimod group (*p < 0.05)
(Fig. 2d, e).
Monocytes infiltration following TBI was reduced by
laquinimod
CCR2 is an important chemokine involved in the re-
cruitment of monocytes to damaged tissues in an in-
flammatory milieu. Axonal injury correlates with
accumulation of microglia/macrophages in EAE [13],
and it has been shown that CCR2 depletion reduced
APP immunoreactivity after TBI [18]. Given that impair-
ment of CCR2 signaling either by genetic deletion or by
pharmacological intervention ameliorates TBI in rodents
[26–29], we hypothesized that reduced monocytes infil-
tration might lead to less neuronal damage.
Flow cytometric analysis revealed that laquinimod
treatment decreased total CCR2+ monocytes, as well as
Ly6C+ monocytes in the brain, immune cells known to
be recruited to the CNS following inflammatory insults
(*p < 0.05) (Fig. 3a, b). Infiltrating monocytes in the brain
were reduced by 66.2% (Average Ly6C+ cell number in
the TBI-water group; 11,907/mouse, in the TBI-
laquinimod group; 4027/mouse) in TBI-laquinimod
group. Tissue staining for CCR2 showed that CCR2+
monocytes were mostly distributed around vessels in
TBI-water group and not affected by laquinimod
(Fig. 3c). These results suggest that the reduced numbers
of CCR2+ cells in TBI-laquinimod tissues are not associ-
ated with a change in distribution of CCR2+ cells.
Laquinimod suppressed inflammation-related genes on
monocytes
To investigate the monocytes’ role on TBI in the acute
phase of TBI, we sorted infiltrated monocytes at 3 days
post injury and performed gene expression analysis
using Nanostring system [19, 20]. Comparing gene ex-
pression changes of the laquinimod-treated TBI group
with that of the water control TBI group, 24 genes were
a
d
b
c
e
Fig. 2 Laquinimod has neuroprotective role on TBI. a Representative × 20 images of APP staining in the corpus callosum and hippocampus on ipsilateral
side of injury (or craniotomy for sham) from each group. b–c Quantification of the APP-positive cells reveals tendency of decreased axonal damage both
in corpus callosum and in hippocampus in the TBI-laquinimod group compared to the TBI-water group (n= 3 mice for each sham group, n= 4 mice for
each TBI group). d Representative × 20 images of doublecortin staining in the dentate gyrus on ipsilateral side of injury (or craniotomy for sham) from
each group. e Quantification of neurogenesis in dentate gyrus reveals a significant increase in TBI-laquinimod group compared to the TBI-water group.
Symbols denote significant differences between groups. Error bars indicate mean ± s.e.m. (n= 5 mice for each group). *p < 0.05, **p< 0.01, ***p< 0.001
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upregulated by laquinimod. On the other hand, more
than half of the genes examined (259/468 genes) were
downregulated by laquinimod. In addition,
inflammation-related genes (Tlr5, Hmgn1, Mapk14,
Map3k7, Tlr2, C4a, Csf1, Pitpnm1, Nr3c1, Gnas, and
Ripk2) and tlr3, tlr4, tlr7, and tlr7 were downregulated
by laquinimod in monocytes (Fig. 4a).
Nitric oxide (NO) derived from the inducible iso-
form of NO synthase (iNOS) is an inflammatory
product implicated in secondary damage from brain
injury, and either iNOS-deficiency or iNOS inhibitors
are protective at the early phase of injury [30–32].
Interleukin 6 (IL-6) is another potential mediator of
TBI [33, 34] and high level of IL-6 in cerebrospinal
fluid (CSF) or serum has reported as high risk for
poor outcomes in human [35, 36]. To address
whether iNOS or IL-6 production were affected by
gene expression changes in monocytes, we performed
quantitative RT-PCR. Quantitative RT-PCR showed a
tendency of decrease in iNOS (34.4%) and IL-6
(26.3%) production in monocytes treated by laquini-
mod (Fig. 4b, c). Taken together the effects of
laquinimod on inflammatory gene expression (about
one-third reduction on a per-cell basis) and on mono-
cyte infiltration (about two-thirds reduction in total
infiltrated cells), we estimate that overall monocyte
inflammatory gene expression in the CNS of
laquinimod-treated mice was lowered by as much as
80%.
TBI-laquinimod microglial gene expression resembles the
sham control group more than TBI-water group
Next, we addressed how laquinimod might affect micro-
glial functions in TBI pathology. The involvement of
microglia in the pathophysiological cascade following
brain injury has long been recognized. As expected, the
injury induced microglial morphological transformation
(ramified, bushy) with increased GFP signal at the site of
damage in the TBI-water group (Fig. 5a). Similarly, TBI-
laquinimod showed increased GFP signal under the
damaged site and microglial distribution nor their
morphology were not altered by the treatment (Fig. 5a).
Next, we sorted microglia and compared gene expres-
sion changes. From the comparison between mice with
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TBI and naïve mice group, we found that 124 genes ex-
pression were elevated in microglia by TBI. Conversely,
there were 112 downregulated genes including transcrip-
tional factors (Atf3, Egr1, Fos, Fosb, Jun, Junb), which are
important for cell proliferation and differentiation.
Among 124 genes that increased their expression after
TBI, most of them did not change their expression after
laquinimod treatment (Fig. 5b). Five genes (Spp1,
HIST1H2AB, Apoe, C4a, and Bhlhe41) slightly elevated
their expression and two genes (Bach and Nedd1) de-
creased their expression. Among 112 genes that de-
creased their expression after TBI, six genes including
transcription factors and macrophage inflammatory pro-
teins (MIP)-1 chemokines (Atf3, Adamts1, Fos, Fosb,
Ccl3, Ccl4) elevated their expression in response to
laquinimod, although the expression level was still sig-
nificantly lower than that of naïve group (Fig. 5c). Up-
regulated genes by laquinimod compared with the TBI-
water group were listed in Fig. 5d. The level of Chi3l3
(chintinase, Ym1), a target gene of IL-4 and STAT6
pathway and one of anti-inflammatory markers, was not
altered by TBI and increased by laquinimod. As de-
scribed above, there were transcriptional factors import-
ant for cell proliferation and differentiation (Atf3, Fosb,
Fos, Egr1, Jun); however, their level were still consider-
ably lower than that of naïve group. Six genes were
downregulated by laquinimod compared with those in
the TBI-water group (Fig. 5e).
Finally, hierarchical clustering analysis was performed
on the genes from each group using the Multi Experi-
ment Viewer (MeV) software. The gene expression clus-
ter of the TBI-water group and the sham-water control
group was the most similar among all the groups. Subse-
quently, the laquinimod-treated TBI and sham group
showed the similarity to TBI-water group and the sham-
water control group (Fig. 2b). It is noteworthy that the
TBI-water group and the TBI-laquinimod group do not
cluster particularly closely. These results indicate that
laquinimod attenuated TBI-microglial gene expression
closer to the sham group.
Discussion
Activation of microglia and infiltration of peripherally de-
rived monocytes are key responses to the injured brain
after TBI. Since laquinimod has been reported to modify
myeloid functions in other CNS inflammatory models, we
wanted to examine if laquinimod treatment will also affect
TBI-induced inflammation. Herein, we provided the ef-
fectiveness of laquinimod for TBI mouse model: First, ad-
ministration of laquinimod was able to prevent the brain
atrophy in the long term, which may have contributed by
preserved axonal integrity and restored hippocampal
neurogenesis. Secondly, laquinimod significantly reduced
monocyte infiltration to the CNS. Finally, laquinimod
promoted microglial phenotype close to the sham control
group rather than TBI-water group.
Functions of laquinimod are diverse. In EAE model,
it has been reported that laquinimod reduced infiltra-
tion of immune cells into the CNS and suppressed
inflammatory T cell responses [37, 38]. Apart from
the effects on myeloid cells, reduction of the lympho-
cyte adhesiveness to VCAM-1 [38], reduced expres-
sion of CCL2, the molecule that regulates the
trafficking of monocytes [12], and decreased chemo-
kine production by dendritic cells [39] with laquini-
mod treatment have also been reported. In vitro
experiments also showed that laquinimod reduced the
activity of pathways including Jun-N-terminal kinase
in LPS-activated microglia [13].
We took advantage of using Ccr2rfp/+ Cx3cr1gfp/+
mice to distinguish microglia and monocytes in the
CNS. We recently described that Ccr2 deletion, but
not Cx3cr1 deletion, reduced cavity volume and
axonal pathology by inhibiting monocyte infiltration
at an early time point (3 days post-injury) following
TBI [18]. In the current study, we found that infiltra-
tion of CCR2+ monocytes after TBI was significantly
and substantially reduced by laquinimod treatment
and that treatment with laquinimod also leads to
similar neuroprotective effects. For instance, the bene-
ficial effects of laquinimod treatment on neurons
were evident by the finding that in treated mice, most
of the neurons showed very low or complete lack of
the axonal damage marker, APP, expression whereas
in untreated mice, the vast majority of the neurons
were positive for APP. Additionally, laquinimod treat-
ment also restored hippocampal neurogenesis.
The mechanisms of protection remains incompletely
defined. Given that impairment of CCR2 signaling
ameliorates TBI in rodents, we propose the hypothesis
that reduced monocyte infiltration underlies some or
all of the benefits we observed. As CCR2 is a chemo-
kine receptor, mostly expressed by peripheral mono-
cytes, which orchestrates the recruitment of these
immune cells to the CNS, it is quite reasonable that
inhibiting monocyte migration either through Ccr2
modification or laquinimod administration might be a
key factor for neuronal rescue following TBI. Interest-
ingly, the majority of the inflammation-related genes
evaluated were downregulated by laquinimod in infil-
trated monocytes; however, the reduction was not so
significant in microglia (Additional file 1). Tendency
of reduced iNOS and IL-6 gene expression in
laquinimod-treated monocytes possibly play a role in
decreased axonal damage (Fig. 2) [40]. Additionally,
the laquinimod downregulated the expression of most
of TLRs (TLR2, 4, 5, 6, and 7) and p38MAPK
(Mapk14), but not c-JUN or NFκB, in monocytes
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(Fig. 4). The TLR signaling pathway activates NFκB,
resulting in the upregulation of many inflammatory
genes (e.g., cytokines, chemokines, COX-2, and iNOS)
[41]. It is possible that laquinimod also attenuates the
activation of inflammatory proteins by minimizing
and/or preventing TLR signaling, leading to inhibition
of inflammatory p38MAPK pathway. However, add-
itional studies are necessary to better clarify this
issue.
The microglial response in TBI is dualistic and
highly dependent upon timing and nature of the in-
jury [42–44]. While CCR2 deficiency impairs mono-
cytes infiltration and improves functional recovery
and neuronal survival (Gyoneva et al. [18]; Hsieh et
al. [27]), CX3CR1 deficiency has showed a time-
dependent effect after TBI, i.e., early protection but
late worsening [43, 44]. Herein, transcription factors
that promote “healthy” microglial phenotype were
significantly downregulated following TBI. Import-
antly, laquinimod treatment did not suppress these
transcript factors, being favorable to healthy micro-
glial phenotype maintenance, which might explain, at
least in part, laquinimod neuroprotective effect.
Hierarchical clustering provided insights into gene
expression patterns of several conditions of microglia.
Naïve pattern was totally different from sham and
TBI groups. Microglia from sham-water group
showed a similar pattern to that from TBI-water
group rather than injured side of TBI-laquinimod
group, which suggests that laquinimod succeeded in
modifying gene expression in TBI towards sham-like
gene pattern.
There is emerging evidence that increased neuroin-
flammation leading to neurodegeneration is relevant
for memory impairment as a result of brain injury
caused by trauma [45], athletic sports [46], or mili-
tary [47]. Chronic traumatic encephalopathy (CTE)
has gained attention, which is seen in people ex-
posed to repetitive head injury [24]. Neuropatho-
logical features of CTE include brain atrophy,
ventricular enlargement, amyloid-β and tau, and
TDP-43 pathologies, many of which might contribute
to cognitive decline [24, 48]. Similar pathological
changes are also commonly found years after a sin-
gle moderate to severe TBI. Laquinimod treatment
at TBI acute phase led to histological improvement
in ventriculomegaly at a later time point, 120-days
post-injury, indicating its potential to prevent long-
term TBI-related neuropathological changes.
Apart from the robust findings, our study has some
limitations. Preliminary gene expression studies, using
nCounter technology and MG468 array, were per-
formed in separately sorted microglia and monocytes
to determine whether further insight into the effects
of laquinimod on myeloid cells might clarify the
beneficial effects of this treatment. The results were
inconclusive and are provided to the scientific com-
munity to increase the data base of information re-
lated to response of myeloid cells to TBI and to
laquinimod.
We focused our experiments on day 3 post injury, when
the number of infiltrating monocytes is at a peak, in order
to demonstrate and characterize potential differences in
the response of infiltrating monocytes and resident micro-
glia to a relevant disease model at a pre-specified time
point. On the other hand, laquinimod shows its effect 3 to
4 days after the administration in EAE [49]. For this rea-
son, we conducted a pretreatment in order to guarantee
laquinimod effects. Further studies need to address the ef-
fect of administration of laquinimod after TBI. Regarding
behavioral and cognitive assessment, there were no cogni-
tive deficits in the TBI group compared to the sham group,
and therefore, we were not able to detect the role of laqui-
nimod on behavioral function (data not shown). One pos-
sibility for this is that the injury was not strong enough to
lead behavioral and cognitive abnormalities. However, des-
pite the lack of functional changes, we provided evidence
that laquinimod present a neuroprotective role in acute
TBI and also prevent the long-term enlargement of lateral
ventricle (Fig. 1). More severe injuries may be required to
emphasize the difference.
In summary, we report a pronounced benefit of laquini-
mod treatment for lateral fluid percussion TBI in adult
mice. Importantly, laquinimod seems to confer neuropro-
tection following TBI by distinctly modulating microglia
and monocyte functions and microglia to promote anti-
inflammatory responses, while modulates monocyte infil-
tration and inhibits their inflammation-related gene ex-
pression. It is worth noticing that laquinimod does not
neutralize nor contradict the function of cells. The current
study brought new insights into molecular and cellular
mechanisms underlying TBI pathophysiology, paving also
a road for the study of laquinimod as a promising thera-
peutic strategy.
Conclusions
TBI is a major risk factor for the development of neuro-
degenerative diseases. The development of effective
therapeutic strategies is a scientific goal of highest prior-
ity in order to prevent secondary damage to primarily
unaffected tissues. Our data indicated for the first time
multifaceted roles of laquinimod, including immuno-
modulatory and neuroprotective mechanisms of action
in response to TBI. Laquinimod is an immunomodula-
tory drug used in the clinical practice for the treatment
of MS. Our findings provide preclinical evidence of
therapeutic benefit of laquinimod in TBI.
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Additional files
Additional file 1: Inflammation-related gene expression changes in
microglia. A, Gene expression of inflammatory-related molecules in microglia
as measured by MG468 chip. B–C, qPCR validation of iNOS (B) and IL-6 (C) in
microglia. We studied 5–7 mice per group from at least three independent
experiments. Bars show mean ± s.e.m. (n = 5). (PDF 97 kb)
Additional file 2: Gene data—TBI and laquinimod. Sheet 1: nCounter
CodeSet Design. Sheet 2: MG468 Isoform Coverage. Sheet 3: MG468
Annotated genes. Sheet 4: Normalized data. Sheet 5: List of all
detected genes. (XLSX 953 kb)
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